Probi
203 SEK +0,5 %Vær den første som følger denne virksomhed
Probi is a biotechnology company. The company is particularly focused on the research and development of probiotics, a bacterium that is found in the human intestinal system. The research areas within the company include the gastrointestinal, immune system, metabolic syndrome, and stress and recovery. The company's customers include larger corporate customers active in the food industry. The company was founded in 1991 and is headquartered in Lund.
Omsætning
618,29 mio.
EBIT %
8,18 %
P/E
56,86
Udbytteafkast, %
0,64 %
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
PROB
Daglig lav / høj pris
193,5 / 203
SEK
Markedsværdi
2,31 mia. SEK
Aktieomsætning
13,22 t SEK
Volumen
66
Seneste videoer
Finanskalender
Delårsrapport
24.10.2023
Årsrapport
26.01.2024
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Symrise | 69,3 % | 69,3 % |
| Fjärde AP-fonden | 9,3 % | 9,3 % |
Premium
Not activated
This content is for our Premium customers only.
Viser Alle indholdstyper
